| Recalls | Screen‐detected cancers | Interval cancers | |||||
|---|---|---|---|---|---|---|---|
| Characteristic | All screens | Number | Proportion (95% CI) | Number |
CDR (95% CI) (per 10 000 screens) |
Number |
ICR (95% CI) (per 10 000 women‐years) |
| All women | 1 026 137 | 38 253 | 3.73% (3.69–3.76%) | 7024 | 68 (67–70) | 1866 | 9.7 (9.2–10.1) |
| Age (years) | |||||||
| 40–49 | 142 700 | 8930 | 6.26% (6.13–6.38%) | 650 | 46 (42–49) | 284 | 10.5 (9.3–11.7) |
| 50–59 | 424 213 | 16 355 | 3.86% (3.80–3.91%) | 2368 | 56 (54–58) | 733 | 9.1 (8.5–9.8) |
| 60–69 | 356 073 | 9660 | 2.71% (2.66–2.77%) | 2768 | 78 (75–81) | 627 | 9.5 (8.8–10.2) |
| 70 or more | 103 151 | 3308 | 3.21% (3.10–3.31%) | 1238 | 120 (113–127) | 222 | 11.7 (10.3–13.4) |
| Socio‐economic status (IRSD), quintile | |||||||
| 1 (most disadvantaged) | 98 683 | 3540 | 3.59% (3.47–3.70%) | 691 | 70 (65–75) | 147 | 7.9 (6.7–9.3) |
| 2 | 231 500 | 8586 | 3.71% (3.63–3.79%) | 1679 | 73 (69–76) | 427 | 9.8 (8.9–10.8) |
| 3 | 199 763 | 7590 | 3.80% (3.72–3.88%) | 1397 | 70 (66–74) | 340 | 9.0 (8.2–10.1) |
| 4 | 160 137 | 6108 | 3.81% (3.72–3.91%) | 1067 | 67 (63–71) | 283 | 9.4 (8.4–10.6) |
| 5 (least disadvantaged) | 331 041 | 12 228 | 3.69% (3.63–3.76%) | 2156 | 65 (62–68) | 664 | 10.7 (9.9–11.5) |
| Time since previous screen (months) | |||||||
| First screen | 148 499 | 13 627 | 9.18% (9.03–9.32%) | 1280 | 86 (81–91) | 254 | 8.8 (7.8–9.9) |
| Less than 15 | 92 484 | 2426 | 2.61% (2.52–2.73%) | 674 | 73 (67–78)* | 86 | 7.8 (6.3–9.6) |
| 15 to less than 27 | 591 503 | 15 248 | 2.58% (2.54–2.62%) | 3355 | 57 (55–59) | 1116 | 9.7 (9.1–10.3) |
| 27 or more | 193 651 | 6952 | 3.59% (3.51–3.67%) | 1715 | 89 (84–93) | 410 | 10.9 (9.9–12.0) |
| Personal history of breast cancer | |||||||
| Yes | 39 086 | 1223 | 3.13% (2.96–3.30%) | 435 | 111 (101–122) | — † | — |
| No | 987 049 | 37 030 | 3.75% (3.71–3.79%) | 6589 | 67 (65–68) | — † | — |
| Personal history of ovarian cancer ‡ | |||||||
| Yes | 5319 | 141 | 2.65% (2.22–3.08%) | 21 | 39 (23–56) | 3 | 4.3 (1.4–13.3) |
| No | 1 020 811 | 38 112 | 3.73% (3.70–3.77%) | 7003 | 69 (67–70) | 1863 | 9.7 (9.3–10.2) |
| First degree family history of breast cancer | |||||||
| Yes | 211 742 | 8090 | 3.82% (3.74–3.90%) | 1744 | 82 (79–86) | 378 | 10.9 (9.9–12.1) |
| No | 814 395 | 30 163 | 3.70% (3.66–3.74%) | 5280 | 65 (63–67) | 1488 | 9.4 (8.9–9.9) |
| Breast density | |||||||
| Yes | 235 476 | 3784 | 3.21% (3.11–3.31%) | 770 | 65 (61–70) | 776 | 17.3 (16.1–18.6) |
| No | 703 213 | 9347 | 2.30% (2.25–2.34%) | 2194 | 53 (52–56) | 958 | 7.1 (6.7–7.6) |
| Breast surgery/biopsy for benign conditions | |||||||
| Yes | 182 562 | 7375 | 4.04% (3.95–4.13%) | 1608 | 88 (84–92) | 491 | 14.6 (13.3–16.0) |
| No | 843 575 | 30 878 | 3.66% (3.62–3.70%) | 5416 | 64 (62–66) | 1375 | 8.6 (8.2–9.1) |
| Hormone replacement therapy (past 6 months) | |||||||
| Yes | 121 189 | 4924 | 4.06% (3.95–4.17%) | 973 | 80 (75–85) | 335 | 14.6 (13.1–16.2) |
| No | 904 850 | 33 325 | 3.68% (3.64–3.72%) | 6049 | 67 (65–69) | 1531 | 9.0 (8.6–9.5) |
| Self‐reported breast symptoms | |||||||
| Yes | 10 455 | 1313 | 12.6% (11.9–13.2%) | 497 | 475 (435–516) | 72 | 36.7 (29.1–46.2) |
| No | 1 015 682 | 36 940 | 3.64% (3.60–3.67%) | 6527 | 64 (63–66) | 1794 | 9.4 (9.0–9.8) |
CI = confidence interval; IRSD = Index of Relative Socio‐economic Disadvantage.
*
CDR is slightly elevated because women deemed to be at high risk were invited for annual screening.
†
ICR by personal history of breast cancer could not be estimated because recurrent and second breast cancers are not routinely reported to cancer registries.
‡
The numbers of screen‐detected and interval cancers in women with personal histories of ovarian cancer were too low for analysis of the influence of this risk factor.